This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Novo Nordisk A/S.
Reference
Jendle J, et al. Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis. Diabetes Therapy : 11 Dec 2020. Available from: URL: https://doi.org/10.1007/s13300-020-00980-1
Rights and permissions
About this article
Cite this article
Smart insulin pens in T1DM smart use of healthcare resources in Sweden. PharmacoEcon Outcomes News 869, 29 (2021). https://doi.org/10.1007/s40274-021-7396-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7396-6